Mid Pharmaceuticals
Market Cap
₹62,954 ₹62,954 Cr.
P/E
29.18
PEG
3.89
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

Base-case growth anchored on India branded generics (9.4% CAGR) and non-US international expansion (13.2% CAGR), with CDMO and MedTech contributing only by FY30.

Bull case requires GLP-1 capturing >15% market share and US biosimilar launch by late FY27, pushing revenue CAGR to 12.5%.

Bear case driven by US tariff imposition and CDMO delay, slashing revenue growth to 5.5% with acute seasonal and pricing risks.

Financial

Business

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material